Opinion|Videos|September 11, 2024
Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions
Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are common misconceptions regarding the timing of therapy initiation and discontinuation?
- What has research shown regarding outcomes for initiating therapy before age 7 years or discontinuing therapy after age 12 years?
- What consideration should clinicians give about the time to first menses after treatment cessation?
Advertisement
Related to this article
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
AAP renews call for raw milk sales ban, cites emerging H5N1 risk
2
Type 1 diabetes update: Immune therapy, screening, and new technology
3
What pediatricians should do when facing a malpractice lawsuit
4
Menstrual concerns in adolescents: What pediatricians should know
5